Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Hemay808 in Healthy Volunteers
NCT04100642Phase 1Completed
- Sponsor
- Tianjin Hemay Biotech
- Start
- Apr 2019
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Hemay028 in atopic dermatitis (AD) (6 arms), sponsored by Tianjin Hemay Biotech. Primary endpoint: Number of adverse events and serious adverse events. Started Apr 2019; status: completed.
02
Drugs
Hemay028
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04100642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04100642.